Objective: Perampanel (PER) is a selective noncompetitive antagonist at a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, the first of its class approved for the adjunctive treatment of partial onset seizures and generalized seizures. This study explored anti-ictogenic and antiepileptogenic effects of PER in rats at different stages of development. Methods: Using a rapid kindling model in postnatal day 14 (P14), P21, P28, and P60 rats, we studied two doses of PER: 1 and 2 mg/kg injected intraperitoneally 30 min before afterdischarge assessment. We also assessed blood and brain concentrations of PER 30 min after the injection. Results: PER 2 mg/kg significantly increased the afterdischarge threshold (ADT) at all ages, whereas PER at 1 mg/kg increased ADT only in P21 rats. PER 2 mg/kg also shortened the afterdischarge duration in P14 and P28 rats. PER increased the number of stimulations required to achieve a stage 4-5 seizure in a dose-dependent manner in P14 and P21 rats, with almost complete elimination of stage 4-5 seizures. At P28, only PER 2 mg/kg increased the number of stimulations required to develop a stage 4-5 seizure. In contrast, PER had no effect on the number of stage 4-5 seizures at P60. We did not observed any age-dependent significant difference in the serum and brain levels of PER 30 min after the injection. Significance: PER exerted anti-ictogenic effects from P14 to P60 independent of brain maturation. PER also exhibited antiepileptogenic effects with a stronger effect in the younger animals.
a-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors have long been suggested to play an important role in ictogenesis and epileptogenesis. 1 Disappointing results in the development of N-methyl-D-aspartate antagonists as well as an anticipated central nervous system-depressant effect of AMPA signaling inhibition dampened research on glutamatergic antagonism to control seizures. 1 However, AMPA antagonists such as 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (competitive) and 2,3-benzodiazepine GYKI52466 (noncompetitive) have demonstrated antiseizure effects in vivo, [2] [3] [4] [5] [6] but their development was stopped because of poor blood-brain barrier penetration and short half-life, respectively. The noncompetitive AMPA antagonist talampanel showed clinical efficacy in epilepsy, 7 but its clinical development was suspended due to a too short half-life and side effects related to peak concentration.
Perampanel (PER) is a new antiepileptic drug (AED). PER is the first clinically available selective AMPA receptor antagonist. PER is approved for the adjunctive treatment of partial onset seizures with or without secondarily generalized seizures [8] [9] [10] [11] and primary generalized tonicclonic seizures. 12, 13 The binding site of PER on the AMPA receptors remains to be determined. 14 The anti-ictogenic effect of PER has been established in different acute seizure models such as maximal electroshock seizure, pentylenetetrazol-induced seizure, and 6-Hz electroshock-induced seizure. 15 Furthermore, PER has been shown to reduce afterdischarge threshold and seizure severity in the amygdala kindling model 16 and to terminate status epilepticus in the lithium-pilocarpine model in rats. 17 The rapid kindling model is a model of limbic epileptogenesis consisting of the occurrence and progressive development of limbic seizures in response to repeated subthreshold stimulation. This model was adapted by Michelson and Lothman 18 to compress the epileptic process into a 2-day protocol to adapt it to the fast-developing brain. This model is considered to be more predictive of clinical efficacy and toxicity than acute seizure models and has permitted assessment of both anticonvulsant and antiepileptogenic properties of various AEDs throughout brain development. 19, 20 This study applied the rapid kindling model to study antiictogenic and antiepileptogenic effects of PER in adult and immature animals at different stages of development from postnatal day 14 (P14) to P28. A rapid kindling protocol was coupled to measurements of PER concentrations in the blood and the brain at the time of afterdischarge parameter evaluation.
Methods

Animals
Male Wistar rats (Charles River, L'Arbesle, France) at P13, P20, P27, and P59 at the time of surgery were used for the experiments. The rats were housed in standard laboratory conditions with controlled temperature/ humidity, a 12-h light/dark cycle (8:00 AM-8:00 PM), and free access to food and water. Studies were approved by the animal ethical institutional review committee (Bichat-Robert Debr e Ethical Committee, Paris, France) and meet stipulations of the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, Bethesda, MD, U.S.A.).
Treatments
PER powder (Eisai Co., Tokyo, Japan) was diluted in 10% dimethylsulfoxide 0.01N HCl in water. Two different doses were studied at the four ages: 1 and 2 mg/kg injected intraperitoneally (i.p.) 30 min before afterdischarge assessment and kindling onset. These were compared with agematched vehicle-injected rats (a single injection per animal for the whole experimentation). The numbers of animals included in the study are reported in Table 1 .
Surgery, kindling procedure, and electroencephalographic recordings Animals were anesthetized with isoflurane and stereotaxically implanted with a bipolar stimulating electrode (Plastics One, Roanoke, VA, U.S.A.) in the left ventral hippocampus. The coordinates from bregma were the following: P13, 3.0 mm posterior, 3.9 mm left, 4.2 mm ventral; P20, 2.9 mm posterior, 3.7 mm left, 3.8 mm ventral; P27, 3.6 mm posterior, 4.9 mm left, 5.0 mm ventral; and P59, 4.8 mm posterior, 5.3 mm left, 6.5 mm ventral. A tripolar recording electrode was wrapped around skull screws superior to the right hemisphere. Electrodes were fixed to the skull with Integrity composite resin (Densply, York, PA, U.S.A.). After surgery, to protect the electrode from damage, P60 adults were housed individually; whereas P21 and P28 animals were housed four per cage and P14 animals were returned to their mothers and siblings. Twenty-four hours after surgery (30 min after injection), the animals were connected to a DS8000 electrical stimulator via DLS100 stimulus isolators (World Precision Instruments, Sarasota, FL, U.S.A.). Electroencephalographic (EEG) acquisition was enabled by the MP100/EEG100B acquisition system and AcqKnowledge software (BIOPAC, Santa Barbara, CA, U.S.A.). The electrical stimulus used for ictogenesis parameter assessment and the kindling protocol was a square-wave biphasic electrical stimulus of 10-s train duration, 20 Hz, and 1-ms pulse duration, delivered every 5 min. At both 30 min and 24 h postinjection, Key Points • Perampanel (2 mg/kg) exerts anti-ictogenic effects independent of brain maturation from P14 to P60
• Perampanel exerts antiepileptogenic effects at P14, P21, and P28 but not at P60
• The different effects of perampanel across development are not explained by drug blood or brain levels Epilepsia, 58 (11) afterdischarge threshold (ADT) and afterdischarge duration (ADD) were assessed at 0.1-mA increments every 5 min. The kindling protocol consisted of 60 trains every 5 min with a current of 0.1 mA over the ADT. During the kindling procedure, the animals were simultaneously video-recorded during the kindling protocol. Behavioral seizures were scored using the Racine scale: 1, motor arrest and twitching vibrissae; 2, chewing, head bobbing; 3, forelimb clonus; 4, forelimb clonus and rearing; and 5, rearing and falling. Kindling progression was analyzed by assessing the number of generalized stage 4-5 seizures (total number of seizures in Fig. 2A ) and the number of stimulations needed to develop a stage 4-5 seizure (reported in Fig. 2B ). The number of stimulations was restricted to 60 even when no stage 4-5 seizures were observed.
Serum and brain concentrations of PER
Brain and blood samples were collected 30 min after 1-mg/kg or 2-mg/kg PER injection (equivalent to the onset of kindling in kindled animals) from unkindled animals and 24 h after kindling onset from kindled animals. For 30-min samples, blood was collected intracardially from unkindled P14-P60 rats 30 min after 1-mg/kg or 2-mg/kg PER i.p. injection. Brains were dissected from the same animals after 10-min saline cardiac perfusion (Table 1 ). For 24-h samples, blood and brains were collected in the same way after kindling retest on the kindled animals. Serum was collected from blood samples by 17,500 g 15-min centrifugation at 4°C.
Two stock solutions containing 1 g/L of PER (Eisai Co., Tokyo, Japan) were prepared in acetonitrile (ACN; highperformance liquid chromatography [HPLC] grade suitable for ultra HPLC instrument) and stored at À20°C. The first one was used to prepare three calibrant solutions at 20, 50, and 200 lg/L by spiking blank serum. The second one was used to prepare three internal quality control solutions at 30, 90, and 180 lg/L by spiking blank serum. The calibrant and control solutions were aliquoted and stored at À20°C until use.
Serum and brain samples were centrifuged at 1,920 g. Then 10 lL of the supernatant was added to 50 lL of sterile water and 200 lL of methylclonazepam (Alsachim, Illkirch Graffenstaden, France; 10 lg/L in ACN) as the internal standard. After vigorous vortexing, the precipitate was centrifuged at 20,000 g for 10 min at 4°C. Finally, 20 lL of the supernatant was mixed with 180 lL of solvent A (described below).
Samples were analyzed using an Acquity UPLC (Waters) with an ACQUITY UPLC HSS C18 (1.8 lm, 2.1 9 150-mm column; Waters). The mobile phase was a mixture of formic acid buffer at 5 mM (solvent A) and 0.1% formic acid in ACN (solvent B). The gradient profile used was (A: B) 50:50 vol/vol at a flow rate of 0.5 mL/min for 0.5 min, followed by a linear gradient to 5:95 vol/vol over 1 min, which was maintained for 0.65 min and returned to 50:50 vol/vol at 1.75 min. Ten microliters of each sample was injected into the C18 reversed-phase column, and the chromatographic separation was performed at 40°C for 2.5 min. Retention time for PER and methylclonazepam was 1.58 and 1.47 min, respectively.
For the detection, a Waters XEVO TQD tandem mass spectrometer was operated using the following settings: capillary voltage = 1.5 kV; source temperature fixed to 650°C with cone and desolvating gas flow, respectively, to 50 and 1,000 L/h; cone and collision energy depending on analyte ( Table 2 ). Quantification was achieved by multiple reaction monitoring in a positive ion mode. The integration of peak area and data analyses were performed using TargetLynx 4.1 software (Waters).
The lowest limit of quantification and the limit of detection were 6.25 and 3.1 lg/L, respectively. The method was validated in the range of PER concentrations from 6.25 to 40,000 lg/L.
Statistical analysis
Data were analyzed using Prism 5 software (GraphPad, San Diego, CA, U.S.A.). Data are expressed as mean AE standard error of the mean. Statistical analysis was performed using Kruskal-Wallis test followed by Dunn post hoc test. The level of significance was set at p < 0.05.
Results
Effects of PER on hippocampal excitability from P14 to P60
Using the rapid kindling model, we investigated the effect of 1 and 2 mg/kg i.p. injections of PER on hippocampal excitability at P14, P21, P28, and P60. At the dose of 2 mg/ kg, PER significantly increased ADT in all age groups (Fig. 1A) . At the dose of 1 mg/kg, PER increased ADT in P21 rats, whereas PER had no effect on ADT in P14, P28, and P60 rats (Fig. 1A) . At the dose of 2 mg/kg, PER also shortened ADD in P14 and P28 rats (Fig. 1B) . At the dose of 1 mg/kg, conversely, PER had no effect on ADD in either age group (Fig. 1B) .
Effects of PER on kindling acquisition from P14 to P60
At P60, PER (1 and 2 mg/kg) had no significant effect on total number of stage 4-5 seizures and number of stimulations needed to achieve the first stage 4-5 seizure as compared with controls ( Fig. 2A,B) . In contrast, in P14, P21, and P28 rats, 2 mg/kg PER significantly decreased the number of stage 4-5 seizures and delayed the occurrence of the first generalized seizure ( Fig. 2A,B) . At the dose of 1 mg/ kg, PER abolished stage 4-5 seizures in P28 and significantly reduced the number of seizures in P14 and P21 animals. This effect was confirmed by a delayed first stage 4-5 seizure in P14 and P21 rats as compared with controls (Fig. 2B) .
Effects of PER on kindling retention from P14 to P60
At retest, 24 h after the start of the kindling procedure, PER (1 and 2 mg/kg) had no significant effect on ADT at all ages tested compared with controls (Fig. 3A) . However, at P14, 2 mg/kg PER increased ADD and at P28, 1 mg/kg PER increased ADD compared with controls (Fig. 3B ).
Brain and serum concentrations of PER at kindling onset and end of kindling protocol from P14 to P60
To interpret adequately the effects of PER, we measured serum and brain concentrations of PER 30 min after an i.p. injection (i.e., at the time of ADT assessment) and correlated them with the anti-ictogenic and antiepileptogenic efficacy (Fig. 4) .
In the serum, 30 min after the injection of PER (a time equivalent that corresponds to the start of the kindling procedure), PER concentrations were not significantly different between the four age groups (Fig. 4A,B) . In the brain 30 min after the administration of 1 mg/kg, PER concentration was significantly increased in P14 and P21 when compared with P60 animals (Fig. 4A) . However, following administration of PER 2 mg/kg, PER concentration was not significantly different between the age groups (Fig. 4B ). Brain/serum ratios after 1 mg/kg or 2 mg/kg PER injection were higher in P14 and P28 compared to those in P60 animals.
At 24 h after onset of kindling, at the time of retest of afterdischarge parameters, serum concentrations following 1 mg/kg or 2 mg/kg PER were substantially reduced in P21, P28, and P60 animals (<5% of PER concentration at 30 min). In P14 rats, however, concentrations were increased compared to the three other age groups, reaching 25% and 26% of PER concentrations at 30 min Similarly, brain concentrations of PER at 24 h were reduced in P21, P28, and P60 animals (<5% of PER concentration at 30 min). In P14 rats, concentrations were increased compared to the three other age groups, reaching 12% and 14% of PER concentrations at 30 min postinjection for 1 mg/kg (p = 0.0004) and 2 mg/kg PER (p = 0.0001), respectively.
Discussion
Our study first explores the properties of PER in the developing brain. First, PER exerts anti-ictogenic effects at 2 mg/kg independent of brain maturation from P14 to P60, measured by an increase of ADT before kindling. The second finding is that PER also exerts antiepileptogenic effects at P14, P21, and P28, which seems to be age-dependent. This effect is not seen at P60; it is observed at both dosages (1 and 2 mg/kg PER) at P14 and P21 and only for 2 mg/kg at P28. These differences are not explained by the brain concentration of PER, except for a possible role in the longer ADD in P14 rats 24 h after kindling.
The AMPA receptor has become a therapeutic target due to its involvement in ictogenesis and epileptogenesis. The levels of expression of the different subunits change during brain development and differently according to the brain structures. [21] [22] [23] Immature neurons have a low expression of GluA2 compared to more mature neurons. 24 GluA2 plays a role in calcium permeability. The immature brain also exhibits higher expression of the flip GluA1 isoform, reducing AMPA receptor desensitization. 25 Thereby, AMPA receptor-mediated calcium signaling increases during development and then gradually declines toward adulthood, contributing to a higher brain excitability in the developing brain. 25 The dynamic changes across development (subunit types and level of expression) might influence the properties of any AMPA antagonist.
Anti-ictogenic properties of PER in adult animals has been established by previous works reporting the data in various acute seizure models and in a status epilepticus model. [15] [16] [17] Recently, a first experimental study proposed that PER might have antiepileptogenic properties because the treatment modified both absence seizure and depressivelike behavior in the WAG/Rij model. 26 In this model, PER at 3 mg/kg/day reduced the number of spontaneous spike and wave discharges at 6 months, but this effect was not sustained after the drug was withdrawn. This suggests a limited antiepileptogenic effect, as observed in the same model with ethosuximide. 27 All available experimental studies of PER have been performed in adult animals. In our study, we explore the effect of two doses of PER on hippocampal excitability and the epileptogenic process during development from P14 to P60. Using a rapid kindling model, which permits the study and comparison of the effect of AEDs during development, 19, 20, [28] [29] [30] we demonstrated for the first time that PER displays anti-ictogenic effects in all age groups. We also report an antiepileptogenic effect that was stronger during kindling acquisition at P14 and P21 than in P28 rats and absent in P60, suggesting a role of the brain development in the antiepileptogenic effect of PER. However, we did not observe any retention of kindling at any age. Using the same model in the developing brain, anti-ictogenic properties have been found with various AEDs: bumetanide, brivaracetam, lamotrigine, retigabine, and topiramate. 20, [28] [29] [30] In our study, the anti-ictogenic effect of PER seems stronger in the younger animals. We show also an age-dependent effect of antiepileptogenic effects of PER in the younger group but an absence of this effect in adults. Until now, only two drugs have been reported to support age-dependent anti-epileptogenic effects: bumetanide and topiramate. 28, 29 Even if these data suggest a particular interest in the drug development in the younger population, the usual path of clinical investigations has been followed, with the first clinical trials in human adult populations except for bumetanide, which has been explored in human newborns first. 31 The apparent age-related effect of PER observed for both anti-ictogenic and antiepileptogenic properties seems not to be related to a pharmacologic effect, but we cannot rule out that drug metabolism differs between age groups, resulting in a higher level during the kindling procedure. When comparing the serum or the brain concentrations 30 min after i.p. injection of PER at 1 mg/kg or 2 mg/kg, two significant differences have been found (lower brain concentration in P60 vs. P14 and P21 for 1 mg/kg). However, the brain/ serum ratio of PER was generally higher in younger animals compared to adults at both doses. We also cannot exclude that a higher brain penetration of PER in younger animals plays a role in our results. This higher brain penetration should not be regarded as a general phenomenon due to the blood-brain barrier immaturity. As an example, we have observed in our previous study the opposite in the agedependent penetration of the brain of brivaracetam, with a higher brain/serum ratio in P60 animals than in younger animals. 20 These findings illustrate the importance of performing drug level measurement in AED experimental studies to draw appropriate conclusions regarding the antiictogenic/antiepileptogenic effect.
In conclusion, PER exhibits an anti-ictogenic effect with consistent efficacy from P14 to P60 in the rapid kindling model. Moreover, PER inhibits the limbic epileptogenic process, with a stronger effect in P14 and P21 than P28, but has no effect at P60. Further investigation would be of interest to understand the underlying mechanisms of the higher antiepileptogenic effect of PER in the developing brain. These developmental differences also suggest assessing the side effect profile (cognitive/behavior) throughout brain maturation.
